- 360 WallStreet
- Posts
- Breaking Out: Pre-market rallies sparked by strong earnings and big rumors!
Breaking Out: Pre-market rallies sparked by strong earnings and big rumors!
Bullseye open at 11EST
In partnership with
Good day, 360!
Here are some of our top movers today. And don’t forget to join Jeff Bishop for a special Bullseye session LIVE at 11AM EST in Market Masters (FREE!) - the hottest trading room around 🔥. Be the best prepared trader on the Street!
FOCUS LIST🔎
GPUS - Up over 150% in the pre-market after reporting better than expected earnings
NCNA - Up over 100% in pre on no discernible news, rumored partnership with Merck & Co.
BCRX - Up over 15% in pre after reporting better than expected earnings
*sponsored by CBDistillery
End your day the right way.
These Enhanced Relief Gummies combine 75mg CBD with 5mg THC to help ease stress, calm anxiety, and relax—without the groggy next-day feel.
Use RLX25 for 25% off your first order and experience why this brand has over 48k 5-star reviews.
/
HOTLIST🔥
GPUS - Up over 150% in the pre-market after reporting better than expected earnings
Hyperscale Data Inc. (GPUS) through its subsidiaries, owns and/or operates data centers at which it mines Bitcoin; and offers colocation and hosting services, and products and services for various industries in North America, Europe, the Middle East, and internationally.
In the pre-market, GPUS announced preliminary Q1 revenue surpassing $25M and guided FY25 revenue of $115M-$125M.
According to Finiviz, based on yesterday’s close the stock had a market cap of $2.1 million.
Shares of GPUS traded up over 13% in the pre-market in reaction to the positive financial results.
The first target for bulls is the pre-market high at $4.64.
Beyond that, $4.80, $5.55 and $6.25 come into play.
Below $4.64, targets to the downside are $4.11, $4, $3.50, $3.30, $2.72, $2 and then a gap fill at $1.37.
NCNA - Up over 100% in pre on no discernible news, rumored partnership with Merck & Co.
NuCana plc (NCNA) is a clinical-stage biopharmaceutical company that engages in the development of medicines to treat patients with cancer.
Posts on X suggest speculation about a potential partnership between NuCana and Merck & Co., driven by NuCana’s ProTide technology and prior clinical trial success with Merck’s Keytruda (pembrolizumab). Specifically, a post mentions rumors of Merck’s interest in NuCana’s promising technology, which could be fueling investor enthusiasm. However, this information is speculative and not confirmed by official sources
Despite the non-official rumors, shares of NCNA traded up over 100% in pre-market trade.
The $0.87 area acted as support in the pre-market and will be an important level to watch.
Above it, targets to the upside are $1, $1.10, $1.28 and then the pre-market high at $1.31. Beyond that, $1.65 and $2 come into play.
Below $0.87, targets to the downside are $0.75, $0.60, $0.50 and then a gap fill at $0.4602.
*together with TheoTrade
Earnings Flips With Don Kaufman:
Member-ONLY Special Deal. 30-Day $$ Back Guarantee.
RARE Bonuses, INCLUDED!
BCRX - Up over 15% in pre after reporting better than expected earnings
BioCryst Pharmaceuticals Inc. (BCRX) is a biotechnology company that develops oral small-molecule and injectable protein therapeutics to treat rare diseases.
In the pre-market this morning, the company reported financial results for the first quarter ended March 31, 2025, and provided a corporate update.
Highlights Include:
Q1 2025 ORLADEYO net revenue of $134.2 million (+51 percent y-o-y)
Full year 2025 ORLADEYO revenue guidance increased to $580 million to $600 million
Company now expects to be profitable for full year 2025, a year ahead of schedule
Company pays down $75 million of debt; saves approximately $23.5 million over life of loan
NDA submitted for ORLADEYO oral granules for children with HAE aged 2-11
U.S. IND open for BCX17725 for Netherton syndrome
Shares of BCRX traded up over 15% in the pre-market in reaction to the news.
The $10 area acted as support in the pre-market and will be an important level to watch.
Above it, targets to the upside are $10.65, $11, $11.50 and then the pre-market high at $11.65. Beyond that, $12, $13 and $14 come into play.
Below $10, targets to the downside are $9.70, $9.50 and then a gap fill at $8.93.
MARKET NEWS 📰
Don't miss out on our MOBILE ALERTS! Some of these alerts have rocketed 🚀past the MOON 🌝. Text “RAGE” to 1-(888) 487-1534 📲.
*Disclosure: By texting “RAGE” to 1-(888) 487-1534, you agree to receive promotional messages sent via an autodialer. You also agree to the terms of service and privacy policy. This agreement isn’t a condition of any purchase. Message frequency varies. Message and data rates may apply. Reply STOP to opt out; HELP for more information.
DISCLAIMER: To more fully understand any Ragingbull.com, LLC ("RagingBull") subscription, website, application or other service ("Services"), please review our full disclaimer located at https://ragingbull.com/disclaimer
FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. Any RagingBull Service offered is for educational and informational purposes only and should NOT be construed as a securities-related offer or solicitation, or be relied upon as personalized investment advice. RagingBull strongly recommends you consult a licensed or registered professional before making any investment decision.
RESULTS PRESENTED NOT TYPICAL OR VERIFIED. RagingBull Services may contain information regarding the historical trading performance of RagingBull owners or employees, and/or testimonials of non-employees depicting profitability that are believed to be true based on the representations of the persons voluntarily providing the testimonial. However, subscribers' trading results have NOT been tracked or verified and past performance is not necessarily indicative of future results, and the results presented in this communication are NOT TYPICAL. Actual results will vary widely given a variety of factors such as experience, skill, risk mitigation practices, market dynamics and the amount of capital deployed. Investing in securities is speculative and carries a high degree of risk; you may lose some, all, or possibly more than your original investment.
RAGINGBULL IS NOT AN INVESTMENT ADVISOR OR REGISTERED BROKER. Neither RagingBull nor any of its owners or employees is registered as a securities broker-dealer, broker, investment advisor (IA), or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization. Employees, owners, and other service providers of https:// ragingbull. com or RagingBull.com LLC are paid in whole or in part by commission based on their sales of Services to subscribers.
RagingBull.com, LLC shall be entitled to recover attorneys’ fees, costs and disbursements. In the event that any suit or action is instituted as a result of doing business with RagingBull. com, LLC and/or its affiliates or if any suit or action is necessary to enforce or interpret these Terms of Service, RagingBull. com, LLC shall be entitled to recover attorneys’ fees, costs and disbursements in addition to any other relief to which it may be entitled.
*Sponsored Content: If you purchase anything through a link in this email other than RagingBull (RB) services, you should assume that we have an affiliate relationship with the company providing the product that you purchase, and that we will be paid in some way. RB is not responsible for any content hosted on affiliate’s sites and it is the affiliate’s responsibility to ensure compliance with applicable laws. We recommend that you do your own independent research before purchasing anything. While we believe in the companies we form affiliate relationships with, please don’t spend any money on these products unless you believe they will help you achieve your goals.
WE MAY HOLD SECURITIES DISCUSSED. RagingBull has not been paid directly or indirectly by the issuer of any security mentioned in the Services except possibly by advertisers in this email. However, Ragingbull.com, LLC, its owners, and its employees may purchase, sell, or hold long or short positions in securities of the companies mentioned in this communication.
Reply